CLOV vs DFTX: Which Stock Is the Better Buy?
Clover Health Investments, Corp. and Definium Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — CLOV vs DFTX, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Clover Health Investments, Corp. (CLOV) | Definium Therapeutics, Inc. (DFTX) | |
|---|---|---|
| Market cap | $2.6B | $2.6B |
| Revenue (latest FY) | $1.92B | $0 |
| Net income (latest FY) | $-85.55M | $-183.79M |
| Revenue growth (5y CAGR) | 23.4% | — |
| Net margin | -4.4% | — |
| Return on equity | -27.7% | -55.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | — |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full CLOV vs DFTX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CLOV's full financials → Open DFTX's full financials →More comparisons
Frequently asked questions
Which is bigger, CLOV or DFTX?
Definium Therapeutics, Inc. is larger by market capitalization — $2.6B versus $2.6B.
Which grows faster, CLOV or DFTX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
CLOV fundamentals → · DFTX fundamentals → · All 1,500+ companies → · Free screener →